Drugs / autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes
autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00706992 | Jun 2008 → Nov 2012 | melanoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00706992 ↗ |
| Known as | anti-MART-1 F5 cells | “The anti-MART-1 F5 cells are currently being studied in other patients in combination with chemotherapy and IL-2 (aldesleukin) therapy.” NCT00706992 ↗ |
| Known as | anti-MART-1 F5 TCR-transduced PBLs | “Patients receive anti-MART-1 F5 TCR-transduced PBLs as in arm I and MART-1:26-35(27L) peptide vaccine emulsified in Montanide ISA-51 subcutaneously (SC) on days 0 and 30.” NCT00706992 ↗ |
| Known as | F5 cells | “These transduced cells (called F5 cells) will be expanded and tested for their anti-tumor activity.” NCT00706992 ↗ |
| Modality | Cell therapy | “the patient's own lymphocytes (type of white blood cell), which are specially selected and genetically modified” NCT00706992 ↗ |
| Route | Intravenous | “Given intravenously (IV)” NCT00706992 ↗ |